Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.

被引：0

作者：

Bachmeier, Beatrice

Sperinde, Jeff

Weidler, Jodi Marie

Lie, Yolanda

Chenna, Ahmed

Winslow, John

Engel, Jutta

Schubert-Fritschle, Gabriele

Sommerhoff, Christian

Petropoulos, Christos J.

Bates, Michael Patrick

Huang, Weidong

Nerlich, Andreas

机构：

[1] Univ Munich, Inst Lab Med, Munich, Germany

[2] Monogram Biosci, San Francisco, CA USA

[3] Cepheid Inc, Sunnyvale, CA USA

[4] Univ Munich, Inst Med Informat Biostat & Epidemiol, Munich, Germany

[5] Univ Hosp Munich, Inst Med Informat Biometry & Epidemiol IBE, Munich, Germany

[6] Home, Sunnyvale, CA USA

[7] Monogram Biosci Inc, LabCorp, Pleasanton, CA USA

[8] Munich Municipal Hosp, Munich, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.593

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

593

引用

页数：1

共 50 条

[1] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
Huang, W.
Lipton, A.
Leitzel, K.
Ali, S. M.
Fuchs, E. M.
Weidler, J.
Chappey, C.
Sperinde, J.
Tan, Y.
Jin, X.
Paquet, A.
Winston, J.
Petropoulos, C.
Kostler, W. J.
Bates, M.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
[2] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
Bayo, J
Mayordomo, JI
Sanchez-Rovira, P
Perez-Carrion, R
Illaramendi, J
Flores, EG
Bueno, JMG
Vazquez, MR
Crespo, C
Palomo, AG
Huelva, HJRJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
[3] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
Antolin, Silvia
Garcia-Caballero, Lucia
Reboredo, Cristina
Molina Diaz, Aurea
Mosquera, Joaquin
Vazquez-Boquete, Angel
Gallego, Rosalia
Paz Santiago, Maria
Concha, Angel
Eva Perez, Maria
Calvo, Lourdes
Garcia-Caballero, Tomas
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
Jaques, Ryan
Xu, Sam
Matsakas, Antonios
HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
[5] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
Lee, Jin Sun
Yost, Susan Elaine
Stiller, Tracey
Blanchard, Suzette
Padam, Simran
Katheria, Vani
Tang, Aileen
Martinez, Norma
Patel, Niki Himat
Sedrak, Mina S.
Waisman, James Ross
Li, Daneng
Sanani, Shamel
Presant, Cary A.
Mortimer, Joanne E.
Yuan, Yuan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2: HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer
Toi, M.
Sperinde, J.
Huang, W.
Saji, S.
Ohno, S.
Nakamura, S.
Iwata, H.
Masuda, N.
Aogi, K.
Bates, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
Perik, Patrick J.
Lub-de Hogge, Marjolijn N.
Gietema, Jourik A.
Jager, Piet L.
Kosterink, Jos G.
de Korte, Sander A.
van Veldhuisen, Drik J.
van der Graaf, Winette T.
Sieijfer, Drik T.
de Vries, Elisabeth G.
ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
[8] Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
Calamac, M.
Minic, I.
Tomasevic, Z.
Oblakovic-Babic, J.
Serovic, K.
Djurmez, O.
Dimitrijevic, M.
Bozovic-Spasojevic, I.
BREAST, 2021, 56 : S82 - S83
[9] HER2 overexpressing metastatic breast cancer.
Spigel D.R.
Burstein H.J.
Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
[10] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
Jia, W.
Wang, T. Z.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555

← 1 2 3 4 5 →